

General information about company	
Scrip code	542650
NSE Symbol	METROPOLIS
MSEI Symbol	
ISIN*	INE112L01020
Name of company	METROPOLIS HEALTHCARE LIMITED
Type of company	
Class of security	Equity
Date of start of financial year	01-04-2019
Date of end of financial year	31-03-2020
Date of board meeting when results were approved	06-02-2020
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	30-01-2020
Description of presentation currency	INR
Level of rounding used in financial results	Lakhs
Reporting Quarter	Third quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited	Unaudited
Segment Reporting	Single segment
Description of single segment	Pathology
Start date and time of board meeting	06-02-2020 14:00
End date and time of board meeting	06-02-2020 17:30
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-10-2019	01-04-2019
B	Date of end of reporting period	31-12-2019	31-12-2019
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	17290.97	50215.19
	Other income	178.49	359.67
	Total income	17469.46	50574.86
2	Expenses		
(a)	Cost of materials consumed	4264.67	12478.97
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	3806.3	11272.72
(e)	Finance costs	183.64	496.2
(f)	Depreciation, depletion and amortisation expense	815.21	2236.77
(f)	Other Expenses		
1	Laboratory testing charges	128.89	437.98
2	Other expenses	4271.75	12460.41
10			
	Total other expenses	4400.64	12898.39
	Total expenses	13470.46	39383.05

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-10-2019	01-04-2019
B	Date of end of reporting period	31-12-2019	31-12-2019
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
3	Total profit before exceptional items and tax	3999	11191.81
4	Exceptional items	0	-686.48
5	Total profit before tax	3999	10505.33
7	Tax expense		
8	Current tax	846.1	2283.3
9	Deferred tax	-76.94	-7.5
10	Total tax expenses	769.16	2275.8
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
14	Net Profit Loss for the period from continuing operations	3229.84	8229.53
15	Profit (loss) from discontinued operations before tax	0	0
16	Tax expense of discontinued operations	0	0
17	Net profit (loss) from discontinued operation after tax	0	0
19	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
21	Total profit (loss) for period	3229.84	8229.53
22	Other comprehensive income net of taxes	-5.44	-114.04

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-10-2019	01-04-2019
B	Date of end of reporting period	31-12-2019	31-12-2019
C	Whether results are audited or unaudited	Unaudited	Unaudited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
23	Total Comprehensive Income for the period	3224.4	8115.49
24	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
25	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
26	Details of equity share capital		
	Paid-up equity share capital	1003.57	1003.57
	Face value of equity share capital	2	2
27	Details of debt securities		
28	Reserves excluding revaluation reserve		
29	Earnings per share		
i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	6.44	16.4
	Diluted earnings (loss) per share from continuing operations	6.42	16.37
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share		
	Basic earnings (loss) per share from continuing and discontinued operations	6.44	16.4
	Diluted earnings (loss) per share from continuing and discontinued operations	6.42	16.37
30	Debt equity ratio		
31	Debt service coverage ratio		
32	Interest service coverage ratio		
33	Disclosure of notes on financial results	Textual Information(1)	

Text Block

Textual Information(1)

NOTES:

1 These financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India.

2 The above unaudited results were reviewed by the Audit Committee at their meeting held on 06 February 2020 and thereafter approved by the Board of Directors at their meeting held on 06 February 2020. The statutory auditors have expressed an unmodified review opinion.

3 The Company has adopted Ind AS 116, effective annual reporting period beginning April 1, 2019 and applied the standard to its leases, retrospectively, with the cumulative effect of initially applying the Standard, recognised on the date of initial application (April 1, 2019). Accordingly, the Company has not restated comparative information, instead, the cumulative effect of initially applying this standard has been recognised as an adjustment to the opening balance of retained earnings as on April 1, 2019. The Company has adopted Ind AS 116 using the cumulative effect method for transitioning.

4 Exceptional items in the financial results for the nine month ended 31 December 2019 includes: -

a) provision for impairment of investment in securities of Infrastructure Leasing & Financial Services (IL&FS) aggregating to Rs.336.48 Lakhs and;

b) provision for Rs.350.00 Lakhs on account of certain old unreconciled balances.

5 Disclosure of segment - wise information is not applicable, as pathology services is the Company only business segment.

6 The Company completed an Initial Public Offer through an offer for sale by the selling shareholders of 1,36,85,095 equity shares of Rs.2 each at price of Rs. 880. The equity shares of the Company got listed on the BSE Limited and National Stock Exchange of India Limited on 15 April 2019. Expenses related to the offer are being borne by selling shareholders.

7 The standalone financial results for the quarter ended 31 December 2018 and nine months ended 31 December 2018 were not subjected to limited review by the Statutory auditors and are as prepared by the Company's management.

8 The Company have elected to exercise the option permitted under section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company have recognised Provision of Income Tax for the nine months ended 31 December 2019 and re-measured its Deferred Tax Assets basis the rate prescribed in the said section. The full impact of this change has been recognised in the Statement of Profit & Loss for the quarter ended 30 September 2019 and nine months period ended 31 December 2019.

9 The Company is in process of acquiring 51% shareholding of Shraddha Diagnostic Centre (I) Private Limited for providing diagnostic and pathological testing services in Ahmedabad, Gujarat as approved in Board Meeting held on 15 January 2020 to strengthen the presence of the Company in the state of Gujarat for purchase consideration of Rs. 936.30 lakhs. The same is expected to be closed within 3 months from the date of approval of the Board.

10 The Board of Directors of the Company have approved the interim dividend of Rs. 8 per equity share (Face value of Rs. 2 each) at the meeting held on 06 February 2020.

11 The results of the Company are available for investors at www.metropolisindia.com, www.nseindia.com and www.bseindia.com.

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results		
Particulars	3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-10-2019	01-04-2019
Date of end of reporting period	31-12-2019	31-12-2019
Whether accounts are audited or unaudited		
Nature of report standalone or consolidated	Standalone	Standalone
1 Segment Revenue (Income)		
(net sale/income from each segment should be disclosed)		
Total Segment Revenue		
Less: Inter segment revenue		
Revenue from operations		
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
Total Profit before tax		
i. Finance cost		
ii. Other Unallocable Expenditure net off Unallocable income		
Profit before tax		
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
Total Segment Asset		
Un-allocable Assets		
Net Segment Asset		
4 Segment Liabilities		
Segment Liabilities		
Total Segment Liabilities		
Un-allocable Liabilities		
Net Segment Liabilities		
Disclosure of notes on segments		

